Breaking News

Novasep’s European Sites Pass FDA Inspections

October 22, 2013

Audits demonstrate custom manufacturing capabilities

Novasep’s European custom manufacturing sites in Le Mans, France and Leverkusen, Germany have successfully passed FDA inspections. The audits took place at the two facilities in June and July 2013.
 
The FDA audit at the Le Mans site was a pre-approval inspection for production of paclitaxel, an anticancer parenteral active ingredient. The audit demonstrates the team’s capability to handle highly potent active pharmaceutical ingredients (HPAPI), including paclitaxel. The Leverkusen facility audit included both a pre-approval inspection of the production of formulated nitroglycerine and an overall cGMP inspection on all products for the U.S. market. 
 

 
“The FDA has tightened up its surveillance and audits,” said Michel Spagnol, chief executive officer at Novasep. “Adhering to regulatory requirements is critical, although it is becoming progressively more challenging across the industry. Our teams’ commitment to quality is impressive. I am very pleased with our continued track record in securing FDA inspection approval and the added assurance these successes give our global customers.”
 

 

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision